NOORULT

Cumberland Pharmaceuticals IncCPIX

NasdaqHealthcarePharmaceutical Preparations
Price (close)
$7.61
Market cap
$114.0M
P/E
—
Revenue (TTM)
$31.3M
Net income
-$10.9M
Dividend yield
19.71%
1-year total return
223.9%
Net margin
-34.9%
Revenue growth
-1.1%
Debt / equity
0.00x

What Cumberland Pharmaceuticals Inc does.

Cumberland Pharmaceuticals Inc. ("Cumberland," the "Company," or as used in the context of "we," "us" or "our"), is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription pharmaceuticals. We are dedicated to our mission of working together to provide unique products that improve the quality of patient care.

Our primary target markets are hospital acute care, gastroenterology and oncology. These medical specialties are characterized by relatively concentrated prescriber bases that we believe can be served effectively by relatively small, targeted sales forces. We promote our approved products through our hospital, field and oncology sales divisions in the United States. We have also established a network of international partners with the needed regulatory and commercial capabilities to register and provide our medicines to patients in their countries.

• Sancuso ® ( granisetron ) transdermal, for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment;

Revenue and profit, by fiscal year.

Fiscal year202020212022202320242025
Revenue$37.4M$36.0M$42.0M$39.6M$37.9M$44.5M
Net income-$3.3M-$3.5M-$5.6M-$6.3M-$6.5M-$2.8M
Free cash flow$5.3M$6.2M$8.4M$5.8M-$678,647$4.8M

More on CPIX.

Figures from Cumberland Pharmaceuticals Inc's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.